Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Bone Miner Res. Author manuscript; available in PMC 2014 February 1.
Published in final edited form as:
PMCID: PMC3547166

Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: results from the University of Washington rapid autopsy series


Qualitative and quantitative bone features were determined in nondecalcified and decalcified bone from 20 predetermined bone sites in each of 44 patients who died with castration resistant prostate cancer (CRPC), some of which received bisphosphonate treatment (BP) in addition to androgen deprivation therapy (ADT). Thirty nine of the 44 patients (89%) had evidence of bone metastases. By histomorphometric analysis, these bone metastases were associated with a range of bone responses from osteoblastic to osteolytic with a wide spectrum of bone responses often seen within an individual patient. Overall, the average bone volume/tissue volume (BV/TV) was 25.7% confirming the characteristic association of an osteoblastic response to prostate cancer bone metastasis when compared to the normal age-matched weighted mean BV/TV of 14.7%. The observed new bone formation was essentially woven bone and this was a localized event. In comparing BV/TV at metastatic sites between patients who had received BP treatment and those that had not, there was a significant difference (28.6% vs 19.3%, respectively). At bone sites that were not invaded by tumor, the average BV/TV was 10.1% indicating significant bone loss due to ADT that was not improved (11%) in those patients who had received BPs. Surprisingly there was no significant difference in the number of osteoclasts present at the metastatic sites between patients treated or not treated with BPs but in bone sites where the patient had been treated with BPs, giant osteoclasts were observed. Overall, 873 paraffin embedded specimens and 661 methylmethacrylate embedded specimens were analyzed. Our results indicate that in CRPC patients, ADT induces serious bone loss even in patients treated with BP. Furthermore, in this cohort of patients, BP treatment increased BV and did not decrease the number of osteoclasts in prostate cancer bone metastases compared to bone metastases from patients who did not receive BP.

Keywords: Histomorphometry, Bisphosphonates, Androgen deprivation, Prostate cancer metastasis, Osteoclasts


Nearly all patients who die of advanced prostate cancer (PCa) have bone metastases (1;2). Bone metastases are associated with bone pain, fracture, nerve and spinal cord compression, and myelophthisis (3-7). Androgen deprivation therapy (ADT), mainstay treatment for metastatic disease in PCa patients, adversely induces osteoporosis and fragility fractures (8). Since 2004, bisphosphonates (BP) have been considered standard care for castration resistant prostate cancer (CRPC) patients with bone metastases as they reduce the risk for skeletal related events (SREs). Zoledronic acid is the most potent of the chemical anti-resorptives and to date, no histomorphometric study evaluating the effects of an anti-resorptive agent on human PCa bone metastases has been published.

To better characterize the bone changes induced by metastatic CRPC, ADT, and BP therapy on both tumor involved and uninvolved bone, we assessed the qualitative and quantitative bone parameters in 20 predetermined sites in 44 patients who died of metastatic CRPC. Each bone specimen from these 20 sites were divided into 2 halves; one was decalcified and paraffin embedded for qualitative assessment and the other, nondecalcified, was directly embedded in methylmethacrylate (MMA) for quantitative bone histomorphometry. Our results confirm bone loss in uninvolved bone specimens from androgen deprived patients and the existence of a spectrum of osteoblastic, to mixed, to osteolytic metastases, frequently in the same patient. Furthermore, BP increased bone volume (BV) in the osteoblastic metastases as expected, but surprisingly did not decrease the number of osteoclasts in metastatic or uninvolved bone biopsy specimens. Giant osteoclasts were observed rarely in bone specimens of patients treated with alendronate and zoledronic acid. Additionally, increased osteoid was observed in both high BV and low BV metastases and osteoclast numbers were significantly higher in low BV BP-treated metastases vs. high BV BP-treated metastases.

Materials and Methods

Tissue acquisition

Samples were obtained from patients who died of metastatic CRPC and who signed written informed consent for a rapid autopsy to be performed ideally within 2 hours of death, under the aegis of the Prostate Cancer Donor Program at the University of Washington (9). The study was approved by the institutional review board at the University of Washington. Bone biopsy specimens of all bone sites, except ribs (a dyke cutter was used for rib biopsies) were obtained using a drill with an attached trephine (11 mm diameter coring drill bit). These specimens were obtained from 20 predetermined anatomical sites (2). Additional cores were obtained from either additional obvious sites of bone metastases or as indicated by the last bone scintigraphy survey.

Bisphosphonate Therapy

Of the 44 patients in the study, 34 were treated with bisphosphonates. Based on notes from the medical charts of multiple patients, the usual BP dosing was as follows: Zoledronic acid (27 patients, 28 if you include one patient who received alendronate and zoledronic acid) the usual regimen was 4 mg IV monthly. This was varied based on patient factors, such as renal function. Some men were in a clinical trial and received zoledronic acid every 3 weeks. For pamidronate (5 patients) the usual regimen was 80 mg IV monthly. One patient received alendronate 70 mg PO weekly.

Tissue processing

Bone samples for qualitative histology were fixed in formalin, decalcified in 10% formic acid and embedded in paraffin. Bone samples for quantitative histomorphometric analysis were fixed in 70% ethanol, and embedded in a methylmethacrylate (MMA) medium without decalcification (10).

Histology and Histomorphometry

Five-micron sections of decalcified paraffin-embedded bone samples were stained with hematoxylin and eosin and assessed by two pathologists for bone and tumor content (MR and LT). Five-micron sections of nondecalcified MMA-embedded bone samples were stained with Goldner’s method for histomorphometric analysis (11). The reagent NBT/BCIP was used to evaluate alkaline phosphatase (ALP) activity. An aqueous coupling azo reactive dye mixture was used to evaluate osteoclast number (acid phosphatase (TRAcP) positivity). All histomorphometric measurements are expressed in accordance with the American Society for Bone and Mineral Research (12). Histomorphometry was performed on a 13.55 mm2 area at 20X magnification Image analysis was conducted with an Olympus BX41 microscope using Bioquant Nova Prime software (Bioquant Image Analysis Corp. Nashville TN). In each biopsy specimen where the number of osteoclasts was greater than 1, osteoclasts were counted and separated into <9 nuclei, 9-12 nuclei, 13-20 nuclei or >20 nuclei groups. Woven bone area was measured using two polarizing filters on Goldner’s and TRAcP stained bone sections where BV/TV was equal or more than 45%. Mineralization was not studied in this cohort of patients.

Statistical analysis

Significance of differences was evaluated using a two-sample equal variance student’s t test with paired observations when appropriate and a two-tailed distribution. p values ≤0.05 indicated statistical significance.


We processed bone samples from 44 rapid autopsies of patients who died with metastatic CRPC. Patient’s demographics and treatments are presented in Supplemental Table 1. The mean age at autopsy was 72.8 years. All patients had received ADT with a median treatment duration of 65.9 months. Thirty-four patients (77%) received BP therapy. Zoledronic acid was the most common BP treatment; among those treated with BP the median treatment duration was 17.2 months (range 1 month to 70 months). One patient received alendronate and zoledronic acid, one patient received only alendronate for 42 months. Five patients received pamidronate for 6 to 22 months. In addition, 29 patients (66%) received secondary hormonal manipulation and 31 patients (71%) received at least one form of chemotherapy.

From a potential of 894 decalcified paraffin embedded samples, 873 were suitable for histological analysis. Five hundred and eighty seven had tumor involvement (67%) accounting for 38 of 44 patients (82%) having at least one bone metastasis. Qualitatively, of the decalcified paraffin embedded metastatic samples 30% were predominantly osteoblastic, 38% were osteoblastic with a small osteolytic component, 9% were osteolytic with a small osteoblastic component, 14% were predominantly osteolytic and 9% had no bone response to tumor (Figure 1A). Two patients were predominantly osteolytic in all bone metastatic sites

Figure 1
(A) Summary of qualitative analysis of bone response in ADT and bisphosphonate treated PCa decalcified paraffin embedded bone metastatic specimens from 44 patients. Histologically we determined the predominant phenotype of each bone metastasis sample. ...

For nondecalcified methylmethacrylate (MMA) embedded samples, of 894 potential samples, 233 (26%) of the bone samples could not be evaluated due to technical reasons. The remaining 661 MMA-embedded samples from 44 patients were analyzed. The main histomorphometric parameters that we measured were: bone volume (BV), new unmineralized bone formation (i.e. osteoid volume), osteoclast numbers, and alkaline phosphatase (ALP). Four hundred and forty-three of the 661 MMA-embedded samples had tumor involvement (67%), accounting for 37 of 44 patients (84%) with at least one bone metastasis (Figure 1B, showing bone volume in all specimens, metastatic or not). This is similar to but not identical to the 64% tumor involvement noted in the paraffin-embedded samples due to different portions of each bone core being used for these two processing methods.

We calculated a weighted mean for BV based on the most comprehensive published analysis of BV in the aging male (13). This weighted mean was based on the age profile of the patients. The weighted mean average BV for our cohort based on age was 14.7%. Of the 661 available MMA embedded samples, 3 were excluded as statistical outliers, 215 (33%) had no tumor with a mean BV of 10.5% (range 2.33-25.42). Of those, 176 (82%) had <14.7% BV and 39 (18%) had >14.7% BV indicating that ADT induces bone loss. Additionally, of the 661 available samples, 443 (67%) had tumor as described above, with 147 (33%) containing tumor with <14.7% BV, and 296 (67%) containing tumor with >14.7% BV indicating a predominantly osteoblastic response in the PCa bone metastases (Supplemental Table 2).

The 443 tumor containing samples were compared to the 215 samples without tumor for various histomorphometric characteristics (Table 1). The mean tumor volume as a percent of tissue volume in the metastatic sites was 24.7%. Overall, there was a considerable amount of bone present in the metastatic sites (range 2.8% to 76.6%; mean 25.7; %BV/TV), compared to uninvolved bone (range 2.3% to 25.4%; mean 10.5; %BV/TV) (Table 1). The significant increases in bone volume (p<0.001), bone surface (p<0.001), trabecular thickness (p<0.001), and trabecular number (p<0.001) in metastatic bone sites were due to the addition of woven bone and osteoid onto preexisting trabeculae and in between a nest of cancer cells within the bone marrow microenvironment. Osteoid, but no woven bone was observed in purely osteolytic lesions. As expected, BV (p<0.001), osteoid area (p<0.001), and ALP (p<0.001) activity were also higher in the metastatic sites vs. uninvolved sites, with 10-fold more osteoid area and more than double the percentage of metastatic sites being positive for ALP compared to the uninvolved bone sites. The osteoid volume compared to total BV was 5 fold higher in the metastatic sites (Table 1). No difference was found in osteoid volume between BP-treated and untreated bone specimens. As expected osteoclast numbers were significantly higher (p=0.005) in metastases than in uninvolved bone (Table 1). However, the osteoclast number per bone surface unit was no different (p=0.660) in metastases and uninvolved bone, revealing that both involved and uninvolved bone had similar osteoclast coverage on the bone surface (Table 1).

Table 1
Histomorphometric analysis of metastatic and non-metastatic bone specimens from 44 patients from the CRPC rapid autopsy series

Our patients had an extremely wide range of BP treatment times (0.8 – 70 months). An analysis was completed for all BP vs. non-bisphosphonate treated (NBP) samples. Metastatic sites in patients receiving BP had a similar tumor volume to equivalent metastatic sites in patients not receiving BP treatment (Table 2A). BV as a percentage of tissue volume (%BV/TV) was significantly greater in BP-treated patient metastatic sites (p<0.001) when compared to metastatic sites of NBP patients (Supplemental Figure 1A through D). There was a significant increase in mean osteoid volume in BP-treated metastatic lesions, (p=0.005), with fewer ALP positive sites present in patients receiving BP. There was no significant difference in the number of TRAcP positive osteoclasts in NBP and BP metastatic specimens, but there was a significant difference in osteoclast coverage of bone surface (p=0.048) in metastatic sites from patients receiving BP treatment versus metastatic sites from NBP patients (Table 2A). In uninvolved samples, BP treatment had no effect on BV (p=0.209), with no significant effect on osteoid volume, ALP positive sites, and osteoclast numbers (Table 2B). In addition, we also elected to confine this analysis to those patients who had been treated for a minimum of 12 months. The results were similar (Supplemental Table 3).

Table 2
Histomorphometric analysis of bone specimens from bisphosphonate and non-bisphosphonate treated patients

To determine if the site of skeletal metastasis influenced the relationship between the tumor and the corresponding bone response, bone histomorphometric parameters in the long bones, vertebrae, sacrum, and other sites, i.e., sternum, ribs and clavicle were compared (Supplemental Table 4). Fifty-four percent (54%) of the long bones had tumor compared to 73%, 74% and 69% in vertebrae, sacrum, and other sites respectively. Larger numbers of osteoclasts were present in the sternum, ribs and clavicle specimens vs. the other bone specimens, reaching 67 per specimen in a 7 month zoledronic acid treated patient (Supplemental Table 4). The high osteoclast numbers may be associated with increased bone remodeling in these more flexible bone sites (Supplemental Table 4D).

Histomorphometric features of metastatic sites from patients treated with BP with > or < 14.7% BV were compared to determine if features other than BV could explain differences in bone formation (Supplemental Table 5). Besides a decrease in ALP activity in the < 14.7% BV samples, no obvious factors were observed. A similar analysis mentioned above was done for patients who received BP or NBP with < or > 14.7% BV and again, no significant differences were observed (Supplemental Table 2). Based on these data, the challenge to identify histomorphometric parameters that are significantly different between the >14.7% and <14.7% BV samples reaches an unanticipated level of complexity.

Therefore, to better define the role of the osteoblasts and osteoclasts in the bone remodeling process extreme ends of the spectrum were examined, i.e., highly osteoblastic (>35.3% BV) and highly osteolytic (<9.1% BV) metastases in BP-treated patients, (Table 3). We selected these cutoffs of 35.3% and 9.1% since they were the mean BV measurements in metastatic sites from patients who received BP with >14.7% and <14.7% BV (Supplemental Table 5). The mean %BV/TV was 49.9 in extremely osteoblastic samples and 6.5 in extremely osteolytic sites (Table 3). Remarkably, even with this significant difference in %BV/TV, osteoid volume and ALP positivity were similar between these two groups. However, the osteoid bone coverage was nearly 4 fold higher in the osteolytic metastatic sites, indicating an important bone forming process in BP treated bone.

Table 3
Histomorphometric analysis of highly osteoblastic and highly osteolytic metastatic bone specimens from bisphosphonate treated patients

A marked increase in osteoclast number (p=0.057) and osteoclast coverage of the bone surface (p=0.003) was observed in the extremely osteolytic sites together with a high osteoid bone coverage indicating a higher bone turnover in osteolytic lesions as compared to osteoblastic lesions (Table 3; Supplemental Figure 1E and F; Supplemental Figure 2). Similar results were observed when we assessed patient-paired osteoblastic and osteolytic bone biopsy specimens from a much smaller subset of 5 BP treated patients with metastatic bone sites that had both extremely osteoblastic (>35.3% BV) and extremely osteolytic (<9.1% BV) metastases (Supplemental Table 6).

To determine BP effects on osteoclasts, we compared the number of osteoclasts found in metastatic biopsy samples from patients untreated and treated with pamidronate, alendronate, and zoledronic acid for <1 year, <2 years, <3 years and >3 years. There was no significant difference between the number of osteoclasts in biopsy samples from each of the groups (Figure 2A). Pamidronate treated metastases had the lowest number of osteoclasts. Alendronate had the highest number of osteoclasts, however, could not be statistically compared with the others groups since only one patient was treated with alendronate. It is noteworthy, that all metastases of one patient in each BP and NBP group had no osteoclasts, suggesting that individual PCa’s may induce no osteoclasts at all.

Figure 2
Osteoclasts were still observed in bone metastases of patients treated with zoledronic acid

To define giant osteoclasts, we sorted the osteoclasts by the number of nuclei visible on the metastatic sections. When we compared the BP groups defined above, we found that 8-or-less-nuclei and 9-12-nuclei osteoclasts were observed in all groups representing the bulk of the osteoclasts present in the metastases (Figure 2B). Giant osteoclasts defined as either containing 13-20 nuclei and more than 20 nuclei, were observed in the patient treated with alendronate, as well as in all zoledronic acid treated patient groups (Figure 3C, E, F and G), they were absent in the pamidronate treated and in NBP treated groups. Concerning osteoclast apoptosis, we found only 3 osteoclasts (out of 1971 reviewed) with pyknotic nuclei in a 4-year zoledronic acid treated metastasis (Figure 3H). However, we noticed that many osteoclasts from the zoledronic acid group had atypical nuclei with angulated nuclear membrane, clear open chromatin and one large irregular nucleolus in each nucleus (Figure 3E).

Figure 3
Morphologic characteristics of bone and osteoclasts of ADT and BP treated bone metastases

To further analyze bone formation in the metastatic specimens from CRPC patients, we measured the woven bone component in 78 biopsies that had more than 45% BV/TV. 45% BV/TV was chosen as a cut off as 45% BV/TV and above is without a discussion an increase of bone mass. Woven bone was found occupying between 15.6% and 98.5% of total bone in osteoblastic biopsies with an average of 88.1%. No difference was observed in woven bone between metastatic specimens from BP and NBP treated patients. Woven bone was formed de novo from the tumor stroma in the bone marrow or deposited directly on lamellar trabeculae (Figure 3 I and J).


At least four processes are known to influence bone structure in PCa bone metastasis: 1) normal bone physiology, 2) systemically and locally secreted tumor factors, 3) androgen deprivation therapy, and 4) bisphosphonate (BP) treatment.

The physiological and perpetual systemic bone remodeling involves balanced and coupled actions of osteoblasts and osteoclasts. All 44 patients in our study were on ADT and the results show that ADT induces serious bone loss similar to post-menopausal osteoporosis in women by systemic activation of osteoclasts. As expected, we observed a huge increase in the number of osteoclasts per uninvolved biopsy specimen -(13). BPs, due to their high affinity for skeletal mineralized bone matrix induce a detrimental effect on osteoclast biology and a systemic and local loss of osteoclast activity. Thus BP treatment has been shown to prevent bone loss in men receiving ADT (14). However, in our study, in uninvolved bone biopsy specimens, BPs were not able to significantly decrease osteoclast number. Consequently, %BV/TV averaged 11.0% in those patients with BP treatment which was not significantly different from %BV/TV (10.1%) measured in bone specimens from NBP- treated patients. These low numbers contribute to the fragility fractures observed in ADT patients (Table 2).

Regarding the elevated osteoclast numbers in BP-treated patients (Table 2 and Figure 2), we found that a small percentage of those osteoclasts were giant osteoclasts, defined here as hypernucleated osteoclasts with greater than 13 nuclei. Previously it was reported that long term alendronate treatment is associated with an increase in the number of osteoclasts, which include distinctive giant hypernucleated detached osteoclasts that are undergoing protracted apoptosis (16). Similarly, we found in a single alendronate treated patient that the number of osteoclasts per biopsy specimen was the highest of all BP treated bone metastases, with 157/mm2 osteoclasts in a metastatic sample. We did not morphologically observe pyknotic nuclei in those alendronate treated osteoclasts, but did not use immunohistochemistry to test DNA fragmentation in our plastic embedded sections. In addition, we did not often observe giant osteoclasts with pyknotic nuclei in bone biopsies from patients treated long term with zoledronic acid. One explanation for the presence of the giant osteoclasts in BP treated specimens is that they may have lost their basic functions by perturbation of the mevalonate pathway but have not as yet disappeared from the bone surface (15;16). The study of apoptosis markers in osteoclasts in paraffin sections of metastasis specimens of this series is warranted.

Local tumor secreted factors, still to be identified, induce the characteristic osteoblastic phenotype of PCa metastasis. Our study, confirming a pilot study previously reported from 12 patients (2), show that the osteoblastic phenotype can manifest as a spectrum of osteoblastic to osteoblastic/osteolytic (mixed) and osteolytic bone responses observed in the same patient at different biopsy sites. Not surprisingly, this study clearly demonstrates that PCa in the bone is predominantly osteoblastic, with an osteolytic component (Figure 1). However this spectrum of lesions has not been previously reported in such detail. Bone scans preferentially expose osteoblastic lesions, thereby underestimating osteolytic lesions. The existence of predominantly osteolytic lesions in a bone site together with osteoblastic lesions in another bone site can be explained either by (1) a maturation of lesions, i.e. osteolytic first and then osteoblastic, or osteoblastic and then osteolytic, or (2) the presence of multiple tumor clones secreting different bone acting factors. This study lacks the knowledge from sampling different bone metastases in each patient at different times as the sampling was made for all patients at death.

In addition to the osteoblastic response of the bone to PCa cells, a high bone turnover is observed in tumor involved bone biopsy specimens as demonstrated by the presence of a high volume of osteoid and a high number of osteoclasts, both in BP treated and NBP treated patients. Osteoid, defined as collagen 1 before mineralization, is 4 fold higher in metastases than in uninvolved bone, indicating the ongoing osteoblastic process in response to the local presence of prostate tumor cells. This suggests that bone response is a localized event. If physiologic bone coupling was maintained then we would expect that an increase in new bone formation would be associated with an increase in osteoclast number. However, in low BV metastases, osteoid bone coverage and osteoclast number are much higher than in high BV metastases suggesting that normal physiologic coupling is perturbed by the tumor (Table 3; Supplemental Figure 2).

Results of this study clearly demonstrate the complex biology taking place in CRPC bone metastases including the dramatic loss of bone induced by ADT, the dramatic addition of woven bone, the limited efficacy of BPs to change the bone responses, and the need to adjust BP treatment to individual tumor related resorption. Finally, this study highlights the persistent need to identify the factor(s) that promote osteoblast activity, so that better targeted therapies can be delivered clinically to improve the quality of life of patients suffering from CRPC skeletal metastases (18;21-23).

Supplementary Material

Supp Figure S1

Supp Figure S2

Supp Table S1

Supp Table S2

Supp Table S3

Supp Table S4

Supp Table S5

Supp Table S6


We would like to thank the patients and their families who were willing to participate in the Prostate Cancer Donor Program, for without them, research of this nature would not be possible. We would also like to acknowledge Bruce Montgomery MD, Susan Ott MD, the rapid autopsy teams and students in the Urology Department at the University of Washington. This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington (RLV is a Research Career Scientist, PHL is a Staff Physician), by the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the NIH grant PO1CA085859, and the Richard M. LUCAS Foundation. CM is a recipient of the Career Development Award from the Pacific Northwest Prostate Cancer SPORE (P50CA097186).

CM accepts responsibility for the integrity of the data. MPR, LDT, PHL, CSH and RLV were responsible for the conception of the experiments. CM, AD, and MPR were responsible for conducting the experiments. CM, AD, MPR, MK, CW, EC and RLV were responsible for analyzing data. CM MPR AD LDT MK CW EC PHL CSH and RLV all participated in the drafting of the manuscript.


Disclosure: Dr. Martine Roudier was employed by Amgen Inc within the past 36 months prior to submission of this manuscript.

Reference List

1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–583. [PubMed]
2. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008;180:1154–1160. [PMC free article] [PubMed]
3. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998;17:331–336. [PubMed]
4. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer. Oncology (Williston Park) 1999;13:1537–1549. [PubMed]
5. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 Jan 13;352:154–164. [PubMed]
6. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918–923. [PubMed]
7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15;12:6243s–6249s. [PubMed]
8. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol. 2008;5:24–34. [PubMed]
9. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003;34:646–653. [PubMed]
10. Lebeau A, Muthmann H, Sendelhofert A, Diebold J, Lohrs U. Histochemistry and immunohistochemistry on bone marrow biopsies. A rapid procedure for methyl methacrylate embedding. Pathol Res Pract. 1995;191:121–129. [PubMed]
11. Recker RR. Bone histomorphometry:Techniques and interpretation. CRC Press; Boca Raton: 1983. pp. 23–29.
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595–610. [PubMed]
13. Bartl R, Frisch B. Biopsy of Bone in Internal Medicine: An Atlas and Sourcebook (Current Histopathology) Vol. 21. Kluwer Academic Publishers; Mar 1, 1993.
14. Serpa NA, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, Dos Reis RB, Pompeo AC, Giglio AD. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2011 Sep 6; [PubMed]
15. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000 Jun 15;88:2961–2978. [PubMed]
16. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009 Jan 1;360:53–62. [PMC free article] [PubMed]
17. Roudier M, Morrissey C, Huang L-Y, Warren A, Rohrbach K, Koelling R, Keller E, Vessella R, Dougall W. Differential Expression of RANK/RANKL/OPG in Prostate Cancer Bone and Soft Tissue Metastases. Cancer Treatment Reviews. 2006 Nov 22;:S1–S53. [PubMed]
18. Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin. 2011;27:55–62. [PMC free article] [PubMed]
19. Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011 Jan 1;48:96–99. [PubMed]
20. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5;377:813–822. [PMC free article] [PubMed]
21. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 2010 Oct 7; [PubMed]
22. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008;7:2160–2169. [PubMed]
23. Tian X, Jee WS, Li X, Paszty C, Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2010 Sep 17; [PubMed]